COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 2.06; I​2 = 74.1%Early treatment75%0.25 [0.04-1.71]1/46922/51375% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Tau​2 = 0.07; I​2 = 68.2%Late treatment32%0.68 [0.54-0.85]342/2,447712/4,79232% improvementLouca1%0.99 [0.93-1.06]casesImprovement, RR [CI]TreatmentControlIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Tau​2 = 37.72; I​2 = 97.5%PrEP99%0.01 [0.00-75.1]0/106,953/20,84999% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Berrocal45%0.55 [0.23-1.31]death5/3126/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Tau​2 = 0.16; I​2 = 37.1%Sufficiency80%0.20 [0.12-0.35]28/427201/43980% improvementAll studies51%0.49 [0.38-0.64]404/3,9877,952/27,21251% improvement21 zinc COVID-19 studiesc19zinc.com Aug 29, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.23; I​2 = 88.3%; Z = 5.21Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]1/14113/377Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.03-1.47]1/14113/37779% improvementKrishnan18%0.82 [0.62-1.09]31/5861/94Improvement, RR [CI]TreatmentControlYao34%0.66 [0.41-1.07]73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]121/1,006424/2,467CT​1Abd-Elsalam (RCT)1%0.99 [0.30-3.31]5/965/95Gadhiya-41%1.41 [0.69-2.57]21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]35/13045/129Elavarasi65%0.35 [0.24-0.56]486 (n)1,201 (n)Tau​2 = 0.10; I​2 = 76.0%Late treatment31%0.69 [0.52-0.91]286/2,026590/4,26131% improvementJothimani90%0.10 [0.01-1.76]0/205/27Improvement, RR [CI]TreatmentControlVogel-González77%0.23 [0.10-0.51]9/19112/58Berrocal45%0.55 [0.23-1.31]5/3126/89Tau​2 = 0.13; I​2 = 28.7%Sufficiency68%0.32 [0.15-0.68]14/24243/17468% improvementAll studies39%0.61 [0.47-0.80]301/2,409646/4,81239% improvement11 zinc COVID-19 mortality resultsc19zinc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.11; I​2 = 71.0%; Z = 3.52Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Carlucci23%0.77 [0.53-1.10]38/41182/521Improvement, RR [CI]TreatmentControlDarban (RCT)6%0.94 [0.84-1.06]10 (n)10 (n)CT​1Tau​2 = 0.00; I​2 = 11.1%Late treatment9%0.91 [0.79-1.05]38/42182/5319% improvementJothimani92%0.08 [0.00-1.26]0/207/27Improvement, RR [CI]TreatmentControlVogel-González71%0.29 [0.20-0.41]34/19136/58Berrocal53%0.47 [0.26-0.83]9/3155/89Tau​2 = 0.06; I​2 = 34.8%Sufficiency67%0.33 [0.21-0.53]43/24298/17467% improvementAll studies47%0.53 [0.30-0.94]81/663180/70547% improvement5 zinc COVID-19 ICU resultsc19zinc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.33; I​2 = 90.8%; Z = 2.16Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand82%0.18 [0.07-0.54]hosp.4/14158/377Improvement, RR [CI]TreatmentControlAsimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​1Tau​2 = 3.11; I​2 = 73.1%Early treatment94%0.06 [0.00-0.95]4/41182/46394% improvementAbd-Elsalam (RCT)4%0.96 [0.86-1.08]hosp. time96 (n)95 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment4%0.96 [0.86-1.08]0/960/954% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementFromonot89%0.11 [0.02-0.48]hosp.6/1107/42Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency89%0.11 [0.02-0.48]6/1107/4289% improvementAll studies95%0.05 [0.01-0.34]10/6277,042/21,44995% improvement5 zinc COVID-19 hospitalization resultsc19zinc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 4.38; I​2 = 94.8%; Z = 3.01Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlAsimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 0.55; I​2 = 25.8%Early treatment91%0.09 [0.01-0.67]1/41122/46391% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Tau​2 = 0.07; I​2 = 68.2%Late treatment32%0.68 [0.54-0.85]342/2,447712/4,79232% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Berrocal45%0.55 [0.23-1.31]death5/3126/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Tau​2 = 0.16; I​2 = 37.1%Sufficiency80%0.20 [0.12-0.35]28/427201/43980% improvementAll studies57%0.43 [0.31-0.58]404/3,9297,952/27,16257% improvement19 zinc COVID-19 serious outcomesc19zinc.com Aug 29, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.28; I​2 = 82.7%; Z = 5.36Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Louca1%0.99 [0.93-1.06]Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP1%0.99 [0.93-1.06]1% improvementSeet (CLUS. RCT)27%0.73 [0.41-1.05]300/634433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP27%0.73 [0.41-1.05]300/634433/61927% improvementFromonot28%0.72 [0.61-0.87]110/18842/52Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency28%0.72 [0.61-0.87]110/18842/5228% improvementAll studies19%0.81 [0.64-1.03]410/822475/67119% improvement3 zinc COVID-19 case resultsc19zinc.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.04; I​2 = 93.3%; Z = 1.74Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Yasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Berrocal45%0.55 [0.23-1.31]death5/3126/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42All studies80%0.20 [0.12-0.35]28/427201/43980% improvement6 zinc COVID-19 sufficiency studiesc19zinc.com Aug 29, 2021Tau​2 = 0.16; I​2 = 37.1%; Z = 5.69Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Thomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment12%0.88 [0.67-1.17]0/580/5012% improvementAbd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Improvement, RR [CI]TreatmentControlDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Tau​2 = 0.00; I​2 = 0.0%Late treatment15%0.85 [0.33-2.22]7/1068/10515% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementAll studies29%0.71 [0.49-1.04]40/79872/77429% improvement4 zinc COVID-19 Randomized Controlled Trialsc19zinc.com Aug 29, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.06; I​2 = 42.2%; Z = 1.76Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Abd-Elsalam (RCT)1%0.99 [0.30-3.31]5/965/95Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment1%0.99 [0.30-3.31]5/965/951% improvementAll studies1%0.99 [0.30-3.31]5/965/951% improvement1 zinc COVID-19 RCT mortality resultc19zinc.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.02Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)Tau​2 = 0.51; I​2 = 48.6%Early treatment39%0.61 [0.18-2.10]1/19913/42739% improvementCarlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Tau​2 = 0.05; I​2 = 49.2%Late treatment20%0.80 [0.62-1.04]186/825243/99520% improvementLouca1%0.99 [0.93-1.06]casesImprovement, RR [CI]TreatmentControlIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Tau​2 = 37.72; I​2 = 97.5%PrEP99%0.01 [0.00-75.1]0/106,953/20,84999% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Tau​2 = 0.00; I​2 = 0.0%Sufficiency84%0.16 [0.10-0.26]23/396175/35084% improvementAll studies52%0.48 [0.35-0.67]243/2,0647,448/23,24052% improvement16 zinc COVID-19 peer reviewed trialsc19zinc.com Aug 29, 20211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.27; I​2 = 88.2%; Z = 4.33Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlDerwand82%0.18 [0.07-0.54]hosp.4/14158/377Thomas (RCT)12%0.88 [0.67-1.17]recov. time58 (n)50 (n)Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Asimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​2Asimi100%0.00 [0.00-0.08]severe case0/27051/86CT​2Carlucci38%0.62 [0.46-0.84]death/HPC54/411119/521Carlucci18%0.82 [0.54-1.25]ventilation29/41162/521Carlucci23%0.77 [0.53-1.10]ICU38/41182/521Krishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera (PSM)37%0.63 [0.44-0.91]death121/1,006424/2,467CT​2Frontera (PSM)24%0.76 [0.60-0.96]death121/1,006424/2,467CT​2Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Abd-Elsalam (RCT)34%0.66 [0.19-2.26]ventilation4/966/95Abd-Elsalam (RCT)6%0.94 [0.55-1.62]no recov.20/9621/95Abd-Elsalam (RCT)4%0.96 [0.86-1.08]hosp. time96 (n)95 (n)Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​2Darban (RCT)6%0.94 [0.84-1.06]ICU10 (n)10 (n)CT​2Gadhiya-41%1.41 [0.69-2.57]death21/5434/229Al Sulaiman (PSM)35%0.65 [0.41-1.01]death35/13045/129Al Sulaiman (PSM)23%0.77 [0.34-1.73]ventilation20/5723/54Elavarasi65%0.35 [0.24-0.56]death486 (n)1,201 (n)Louca1%0.99 [0.93-1.06]casesIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Seet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Seet (CLUS. RCT)27%0.73 [0.41-1.05]cases300/634433/619OT​1Yasui92%0.07 [0.01-0.54]ventilation1/206/9Jothimani90%0.10 [0.01-1.76]death0/205/27Jothimani92%0.08 [0.00-1.26]ICU0/207/27Vogel-González77%0.23 [0.10-0.51]death9/19112/58Vogel-González71%0.29 [0.20-0.41]ICU34/19136/58Vogel-González68%0.32 [0.16-0.63]recov. time191 (n)58 (n)Berrocal45%0.55 [0.23-1.31]death5/3126/89Berrocal53%0.47 [0.26-0.83]ICU9/3155/89Gonçalves82%0.18 [0.08-0.36]severe case7/55145/214Fromonot89%0.11 [0.02-0.48]hosp.6/1107/42Fromonot28%0.72 [0.61-0.87]cases110/18842/52zinc COVID-19 outcomesc19zinc.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home